TrialCompass™ TCL
Back to trials
Not yet recruitingPriority 4 · Lower priorityNCT05343377

A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This is a research study collecting clinical information and/or biological samples from patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

Who can join (key eligibility)

  • Age 18 Years to 80 Years years
  • Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

circulate free methylated EBV DNA (DIAGNOSTIC_TEST): Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS

  • circulate free methylated EBV DNA

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is ENKTL?

Plain-language overview of ENKTL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

NCT05343377

Status: Not yet recruiting | Priority: Lower

Plain-language summary

This is a research study collecting clinical information and/or biological samples from patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

Who can join

  • Age 18 Years to 80 Years years
  • Newly diagnosed, not yet treated

What's being tested

circulate free methylated EBV DNA (DIAGNOSTIC_TEST): Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS

Drugs / treatments: circulate free methylated EBV DNA

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 72 patients

Primary endpoint: Assessing the accuracy of circulating free methylated EBV DNA in predicting 2-year PFS in patients with newly diagnosed ENKTCL

Ages: 18 Years to 80 Years

Start date: 2022-06-01 | Est. completion: 2028-06-01

Locations

0 US sites · 1 total

Contact

wei xu | xuwei10000@hotmail.com | 025-68306034

Sponsor: The First Affiliated Hospital with Nanjing Medical University (OTHER)

Tags

ENKTL · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05343377

Prepared using TrialCompass (trialcompass.com) on August 18, 2026. For informational purposes only. Always discuss with your healthcare team.